drugset / Trial / NCT03844048

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

NCT03844048

Phase 3 Active not recruiting 165 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Timeline

Start
2019-09-06
Primary completion
2027-08
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule Oral